PhenoSense HIV is a phenotypic HIV drug resistance assay and is the most widely
used phenotypic test today. The success of PhenoSense HIV is based on the
quality of the test - utilizing proprietary leading-edge technology for a
direct, rapid and precise measure of a patient's virus' sensitivity to
antiretroviral drugs. Test results allow healthcare professionals to review the
level of susceptibility or resistance that a person has to each antiretroviral
drug in order to design an individualized treatment plan. PhenoSense HIV drug
resistance results are also provided with one component of viral fitness, or
Replication Capacity (RC).
The report form includes drug resistance information for all of the approved
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
Features and benefits of the PhenoSense HIV assay:
-
Provides direct measurement of drug susceptibility
-
Measures quantitative susceptibility data -- can measure partial susceptibility
and hypersusceptibility
-
Uses susceptibility cutoffs to determine when the likelihood of response begins
to decrease
Includes logical, easy-to-read report form
-
Gives accurate results using plasma samples with viral loads as low as 500 HIV
RNA copies/mL
-
Supplements resistance results with replication capacity information to
evaluate viral fitness
Click here to download sample report
Click here to download
slide presentation featuring vector and transfections schematics.
Reference: A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 – Antimcrobial Agents and Chemotherapy
For more information on Monogram assays, services and pricing, please contact us.
